Roche/Genetech discover resistance mechanism to Tecentriq

IMvigor201 trial 의 responder 와 non-responder 의 biomarker study 를 ESMO 에 발표하였다.

Resistance 의 원인은 TGF-beta.

TGF-beta 가 microenvironment 에서 stromal barrier 를 만들어, T cell penetration 을 저해한다는 내용.

링크

Advertisements

Genentech’s new combo pipelines

atezolizumab + entinostat (HDAC1,3 inhibitor)

atezolizumab + CD47

CD47

  • Integrin associated protein
  • immunoglobulin superfamily
  • immune and angiogenic response
  • over expressed in cancer cells
  • anti-CD47 antibody – cancer cell phagocytosis by macrophage & initiated anti tumor T-cell response

CD47TumAndImmunoFig5

FDA grants atezolizumab accelerated approval as frontline therapy in advanced bladder cancer

Atezolizumab 이 작년 bladder cancer 에서 런칭한 이후 1년만에 first line therapy 로 업그레이드 되면서, 이 암종에서 standard of care 가 될 것으로 보인다.

1. Patients with advanced bladder cancer who are not eligible for standard cisplatin chemo

2. Based on data from the single-arm phase II IMvigor210 trial

3. ORR 23.5%, CR 6.7%

http://www.onclive.com/web-exclusives/fda-approves-frontline-atezolizumab-for-some-bladder-cancer-patients

http://www.roche.com/media/store/releases/med-cor-2017-04-18.htm